Trial · NCT01712230

Females, Aging, Metabolism, and Exercise

NCT01712230, Not applicable, Completed, University of Colorado, Denver; results first posted 2019-11-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Females, Aging, Metabolism, and Exercise. Trials, record NCT01712230. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01712230

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Females, Aging, Metabolism, and Exercise
NCT number: NCT01712230
Status: Completed
Phases: Not applicable
Enrollment: 47 participants, actual
Lead sponsor: University of Colorado, Denver
Conditions: Obesity
Interventions: GnRH agonist, Supervised cardiovascular exercise, Placebo
First posted: 2012-10-23
Last updated: 2019-11-22
Results first posted: 2019-11-22

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Physical Activity Energy Expenditure (PAEE)	Change from baseline to 6 months	PAEE will be calculated as: TEE - REE - TEF, where TEE is total energy expenditure (measured by doubly-labeled water), REE is resting energy expenditure (measured by indirect calorimetry), and TEF is the thermic effect of feeding (estimated using a constant).
Secondary	Total Fat Mass	Change over 6 months	Total Fat mass as measured by DXA
Secondary	Total Fat Free Mass	Change over 6 months	Total Fat Free Mass as measured by DXA

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Physical Activity Energy Expenditure (PAEE)	Change from baseline to 6 months	Placebo: One participant dropped because they got a new job. GnRH agonist+exercise: One participant dropped because of a health problem unrelated to the study. Results from five participants were not included in the analysis because they did not meet the exercise compliance threshold (completed \<70% of exercise sessions).	kcal/day	MEAN
SECONDARY	Total Fat Mass	Change over 6 months		kg	MEAN
SECONDARY	Total Fat Free Mass	Change over 6 months		kg	MEAN

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Physical Activity Energy Expenditure (PAEE)	Placebo	74.5	Standard Error 77.9	kcal/day
Change in Physical Activity Energy Expenditure (PAEE)	GnRH Agonist	-10.2	Standard Error 63.6	kcal/day
Change in Physical Activity Energy Expenditure (PAEE)	GnRH Agonist + Exercise	61.0	Standard Error 66.4	kcal/day
Total Fat Mass	Placebo	0.73	Standard Error 0.68	kg
Total Fat Mass	GnRH Agonist	1.66	Standard Error 0.41	kg
Total Fat Mass	GnRH Agonist + Exercise	0.89	Standard Error 0.60	kg
Total Fat Free Mass	Placebo	0.1	Standard Error 0.34	kg
Total Fat Free Mass	GnRH Agonist	-0.69	Standard Error 0.34	kg
Total Fat Free Mass	GnRH Agonist + Exercise	-0.66	Standard Error 0.59	kg

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	11
Overall Study	STARTED	GnRH Agonist	18
Overall Study	STARTED	GnRH Agonist + Exercise	18
Overall Study	COMPLETED	Placebo	9
Overall Study	COMPLETED	GnRH Agonist	14
Overall Study	COMPLETED	GnRH Agonist + Exercise	11
Overall Study	NOT COMPLETED	Placebo	2
Overall Study	NOT COMPLETED	GnRH Agonist	4
Overall Study	NOT COMPLETED	GnRH Agonist + Exercise	7

Source ClinicalTrials.gov

Adverse events27

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea/vomiting	Gastrointestinal disorders	Placebo	0	10	0
other	Nausea/vomiting	Gastrointestinal disorders	GnRH Agonist	0	14	0
other	Nausea/vomiting	Gastrointestinal disorders	GnRH Agonist + Exercise	1	18	1
other	Dizziness/Hot Flash	Endocrine disorders	Placebo	1	10	1
other	Dizziness/Hot Flash	Endocrine disorders	GnRH Agonist	0	14	0
other	Dizziness/Hot Flash	Endocrine disorders	GnRH Agonist + Exercise	2	18	2
other	Bruising/tenderness from study procedure	Skin and subcutaneous tissue disorders	Placebo	0	10	0
other	Bruising/tenderness from study procedure	Skin and subcutaneous tissue disorders	GnRH Agonist	1	14	1
other	Bruising/tenderness from study procedure	Skin and subcutaneous tissue disorders	GnRH Agonist + Exercise	1	18	1
other	Mental state change	Psychiatric disorders	Placebo	0	10	0

1 to 10 of 27Source ClinicalTrials.gov

See all 27 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	10
Total, all-cause mortality	GnRH Agonist	0	14
Total, all-cause mortality	GnRH Agonist + Exercise	0	18
Total, other adverse events	Placebo	3	10
Total, other adverse events	GnRH Agonist	4	14
Total, other adverse events	GnRH Agonist + Exercise	4	18
Total, serious adverse events	Placebo	0	10
Total, serious adverse events	GnRH Agonist	0	14
Total, serious adverse events	GnRH Agonist + Exercise	0	18

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33150745	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P50HD073063	Bioenergetic and Metabolic Consequences of the Loss of Gonadal Function	KOHRT, WENDY M	UNIVERSITY OF COLORADO DENVER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT	2012 to 2017

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01712230

GET https://conductscience.org/api/trials/v1/NCT01712230/events?page=2

API reference For AI assistants